Adaptive immune system mainly comprises T cell and B cell, which carries out their function by binding to specific antigen with unmatched precision, via T and B cell receptors (TCR and BCR). This high specificity of antigen-TCR/BCR binding renders the precise detection and elimination of pathogenic antigens by adaptive immunity. TCR/BCR genes are our most diverse set of genes, distinguishing one individual from another. It does this by generating autologous extraordinary diversity in the receptors, ranging from 1015 to 1025 for each chain of the rearranged receptors.
The adaptome is the sum-total of expressed T and B cell receptor genes in a sample, composed of seven chains, including the alpha/beta and gamma/delta chains for T cells, and heavy/lambda or kappa chains for B cells. The immune repertoire is the sum-total of the individual clonotypes within one chain, including individual complementarity-determining regions (CDR) 3 sequences. The breadth and depth of the true adaptome creates hope for novel diagnostics and/or disease burden assessments for cancers, as well as companion diagnostics for cancer therapies. Integrating studies of the peripheral blood, lymph nodes, and tumor allow dynamic interrogation of the alterations occurring with age, treatment, and response to emergent and established therapies.
This Research Topic entitled " Adaptive Immune Biomarker Signature for Cancer" aims to elucidate the patterns of the adaptive immune system via immune repertoire sequencing for cancers. Furthermore, we hope to develop novel strategies and approaches to identify multi-omics biomarkers based on immune repertoire signature and its cross-talk with others.
Research related to immunological patterns and biomarker discovery from molecular immunology, cellular immunology, immune secretomics, and immune modulators/regulators prospects, related to cancers are welcome in this Research Topic. Subtopics include but are not limited to the following:
(1) Immune repertoire biomarker profiling for cancers and precancerous lesions in peripheral blood;
(2) Immune repertoire profiling of tumor infiltration T cells and its correlation with clinical outcomes in cancers;
(3) Immune repertoire signature and its spatial correlation with immune microenvironment and in situ immune secretome in tumor tissues;
(4) Prognostic immune repertoire biomarker discovery for cancer immunotherapy;
(5) Identify the correlation between TCR/BCR and immunological patterns on single-cell level;
(6) Immune repertoire profiling for unconventional T cells, including ?dT, iNKT, MAIT, etc, in cancers.
(7) Crosstalk between immune repertoire and other omics studies, e.g gut microbiome, metabolomics, transcriptomics, etc.
Please NOTE: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of the scope for this section and will not be accepted as part of this Research Topic.
Adaptive immune system mainly comprises T cell and B cell, which carries out their function by binding to specific antigen with unmatched precision, via T and B cell receptors (TCR and BCR). This high specificity of antigen-TCR/BCR binding renders the precise detection and elimination of pathogenic antigens by adaptive immunity. TCR/BCR genes are our most diverse set of genes, distinguishing one individual from another. It does this by generating autologous extraordinary diversity in the receptors, ranging from 1015 to 1025 for each chain of the rearranged receptors.
The adaptome is the sum-total of expressed T and B cell receptor genes in a sample, composed of seven chains, including the alpha/beta and gamma/delta chains for T cells, and heavy/lambda or kappa chains for B cells. The immune repertoire is the sum-total of the individual clonotypes within one chain, including individual complementarity-determining regions (CDR) 3 sequences. The breadth and depth of the true adaptome creates hope for novel diagnostics and/or disease burden assessments for cancers, as well as companion diagnostics for cancer therapies. Integrating studies of the peripheral blood, lymph nodes, and tumor allow dynamic interrogation of the alterations occurring with age, treatment, and response to emergent and established therapies.
This Research Topic entitled " Adaptive Immune Biomarker Signature for Cancer" aims to elucidate the patterns of the adaptive immune system via immune repertoire sequencing for cancers. Furthermore, we hope to develop novel strategies and approaches to identify multi-omics biomarkers based on immune repertoire signature and its cross-talk with others.
Research related to immunological patterns and biomarker discovery from molecular immunology, cellular immunology, immune secretomics, and immune modulators/regulators prospects, related to cancers are welcome in this Research Topic. Subtopics include but are not limited to the following:
(1) Immune repertoire biomarker profiling for cancers and precancerous lesions in peripheral blood;
(2) Immune repertoire profiling of tumor infiltration T cells and its correlation with clinical outcomes in cancers;
(3) Immune repertoire signature and its spatial correlation with immune microenvironment and in situ immune secretome in tumor tissues;
(4) Prognostic immune repertoire biomarker discovery for cancer immunotherapy;
(5) Identify the correlation between TCR/BCR and immunological patterns on single-cell level;
(6) Immune repertoire profiling for unconventional T cells, including ?dT, iNKT, MAIT, etc, in cancers.
(7) Crosstalk between immune repertoire and other omics studies, e.g gut microbiome, metabolomics, transcriptomics, etc.
Please NOTE: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of the scope for this section and will not be accepted as part of this Research Topic.
